Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway

<div>Correlations between COX2 expression and three cancer-related immune factor types. (a) Correlation between COX2 expression and immunoinhibitors in HCC. (b) Correlation between COX2 expression and immunostimulator in HCC. (c) Correlation between COX2 expression and lymphocyte in HCC.</div>

Journal of Oncology

fig4

Figure 4

Figure 4: Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway 